Literature DB >> 11478426

Neurotransmission in HIV associated dementia: a short review.

E Koutsilieri1, V ter Meulen, P Riederer.   

Abstract

Human immunodeficiency virus (HIV) infection is frequently associated with specific neurological and psychiatric symptoms. Our understanding of how HIV-related CNS deficits develop is still preliminary and the cause remains obscure. However, some clues have emerged which may clarify uncertainties. Following a brief discussion of the epidemiology underlying neuropathological mechanisms and clinical symptoms in HIV-infected patients, we focus our attention on neurochemical data obtained by studies in humans and rhesus monkeys which provide information on the effect of the retroviral infection on neurotransmission and assist in the evaluation of potential therapeutic treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478426     DOI: 10.1007/s007020170051

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  20 in total

1.  Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Authors:  C Scheller; G Arendt; T Nolting; C Antke; S Sopper; M Maschke; M Obermann; A Angerer; I W Husstedt; F Meisner; E Neuen-Jacob; H W Müller; P Carey; V Ter Meulen; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

Review 2.  Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond.

Authors:  Mike Sathekge; Alicia McFarren; Ekaterina Dadachova
Journal:  Nucl Med Commun       Date:  2014-08       Impact factor: 1.690

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

4.  COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.

Authors:  Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  Genetic variation in alcohol dehydrogenase is associated with neurocognition in men with HIV and history of alcohol use disorder: preliminary findings.

Authors:  Rowan Saloner; Emily W Paolillo; Maulika Kohli; Sarah S Murray; David J Moore; Igor Grant; Mariana Cherner
Journal:  J Neurovirol       Date:  2020-01-13       Impact factor: 2.643

6.  Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter.

Authors:  Yaxia Yuan; Xiaoqin Huang; Narasimha M Midde; Pamela M Quizon; Wei-Lun Sun; Jun Zhu; Chang-Guo Zhan
Journal:  ACS Chem Neurosci       Date:  2015-02-19       Impact factor: 4.418

Review 7.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

Review 8.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Authors:  Mark J Ferris; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

9.  Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease.

Authors:  Rowan Saloner; Mariana Cherner; David J Grelotti; Emily W Paolillo; David J Moore; Robert K Heaton; Scott L Letendre; Adarsh Kumar; Igor Grant; Ronald J Ellis
Journal:  Brain Behav Immun       Date:  2020-09-20       Impact factor: 7.217

10.  Imaging dopaminergic dysfunction as a surrogate marker of neuropathology in a small-animal model of HIV.

Authors:  Dianne E Lee; William C Reid; Wael G Ibrahim; Kristin L Peterson; Margaret R Lentz; Dragan Maric; Peter L Choyke; Elaine M Jagoda; Dima A Hammoud
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.